# US 2017/0362656 A1 · miRNA-BASED UNIVERSAL SCREENING TEST (UST)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362656 A1
- Document ID: US20170362656A1
- Status: Published application
- Kind: A1
- Application number: 15/606,747
- Filed: 2017-05-26
- Published: 2017-12-21
- Earliest claimed: 2011-04-18
- Assignees: Diamir, LLC
- Applicants: Diamir, LLC
- Inventors: Samuil R. Umansky; Kira S. Sheinerman; Vladimir Tsivinsky
- Web page: https://patentgrep.com/patent/US20170362656A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described are methods for early noninvasive or minimally invasive detection of pathological changes in organ systems/organs/tissues/cells by quantifying organ system-/organ-/tissue-/cells type-enriched miRNA in bodily fluids.

## Claims

### Claim at position 1

1-168. (canceled)

### Claim 169

A method for selecting subjects for administering one or more disease-specific diagnostic tests to identify a specific pathology in an organ, which method comprises:
a. for each of at least two different organs, measuring the level of one or more biomarker miRNAs in a bodily fluid sample collected from a subject of interest, wherein the bodily fluid is selected from the group consisting of blood plasma, serum, urine, and saliva;
b. for each of the biomarker miRNAs measured in step (a), measuring the level of a normalizer miRNA in the same bodily fluid sample collected from the subject of interest;
c. calculating the ratio of the level of the biomarker miRNA measured in step (a) to the level of the normalizer miRNA measured in step (b) for each of said organs;
d. comparing the ratio calculated in step (c) with a corresponding control ratio for each of said organs, wherein the corresponding control ratio was determined in a corresponding bodily fluid collected from the subject of interest in the past, or from a different subject or a population of subjects without pathology of the respective organs, and
e. administering one or more disease-specific diagnostic tests to the subject of interest when for at least one biomarker miRNA measured in step (a) the ratio calculated in step (c) is greater in the bodily fluid sample collected from the subject of interest than the corresponding control ratio.

### Claim 170 (depends on 169)

The method of claim 169, further comprising determining for at least one of said organs whether the pathology is a cancer or an inflammation, which method comprises:
f. calculating the ratio of the level of one or more biomarker miRNAs to the level of one or more normalizer miRNAs in a bodily fluid sample collected from the subject of interest, wherein the bodily fluid is selected from the group consisting of blood plasma, serum, urine, and saliva;
g. comparing the ratio(s) calculated in step (f) with corresponding predetermined ranges of ratios characteristic of cancer and inflammation, and
h. (i) determining that the pathology is a cancer when the ratio(s) calculated in step (f) is within the predetermined range characteristic of cancer, or (ii) determining that the pathology is an inflammation when the ratio(s) calculated in step (f) is within the predetermined range characteristic of inflammation, wherein
i. the pathology relates to an organ of the respiratory system and the biomarker/normalizer miRNA pairs are selected from the group consisting of miR-34b/miR-155, miR-486b-5p/miR-146b-5p, and miR-192/miR-146b-5p, or
ii. the pathology relates to an organ of the gastrointestinal (GI) system and the biomarker/normalizer miRNA pairs are selected from the group consisting of miR-215/miR-30e-3p, miR-215/miR-194, miR-215/miR-203, miR-203/miR-148a, miR-194/miR-148a, miR-194/miR-192, miR-192/miR-203, or
iii. the pathology relates to an organ of the respiratory system or the gastrointestinal (GI) system and the biomarker/normalizer miRNA pairs are selected from the group consisting of miR-17-5p/miR-155, miR-192/miR-155, miR-215/miR-155, miR-192/miR-30e-3p, miR-155/miR-30e-3p, and miR-146b-5p/miR-30e-3p, or
iv. the biomarker miRNA associated with cancer or inflammation is selected from the group consisting of Let-7 family, miR-10b, miR-17-92 family, miR-21, miR-29a, miR-31, miR-34a, miR-106a, miR-106b, miR-125a-5p, miR-125b, miR-126, miR-146a, miR-146b, miR-150, miR-155, miR-184, miR-195, miR-200/141 family, miR-210, miR-221, miR-222, miR-223, miR-373, miR-375, miR-423-5p, miR-451, miR-486.

### Claim 171 (depends on 169)

The method of claim 169, wherein the corresponding control ratio is the ratio of the levels of the same biomarker and normalizer mRNAs in a similarly processed bodily fluid sample from the same subject collected in the past.

### Claim 172 (depends on 169)

The method of claim 169, which method comprises a step of collecting the bodily fluid sample from the subject of interest prior to step (a).

### Claim 173 (depends on 169)

The method of claim 169, wherein the level of the biomarker and normalizer mRNAs is determined using RT-PCR.

### Claim 174 (depends on 169)

The method of claim 169, wherein, prior to measuring the biomarker and normalizer miRNA levels, miRNAs are purified from the bodily fluid sample.

### Claim 175 (depends on 169)

The method of claim 169, further comprising the step of reducing or eliminating degradation of miRNA in the bodily fluid sample.

### Claim 176 (depends on 169)

The method of claim 169, wherein the bodily fluid is blood plasma.

### Claim 177 (depends on 169)

The method of claim 169, further comprising administering a treatment to the subject of interest.

### Claim 178 (depends on 169)

The method of claim 169, wherein
step (c) involves:
(1) calculating, using a suitably programmed processor, the ratio of the level of the biomarker miRNA measured in step (a) to the level of the normalizer miRNA measured in step (b) for each of said organs;
(2) calculating, by the processor and based on the ratio determined in step (1), a first probability based on a first predefined probability distribution curve, wherein the first predefined probability distribution curve corresponds to pathologies of each of said organs;
(3) calculating, by the processor and based on the ratio determined in step (1), a second probability based on a second predefined probability distribution curve, wherein the second predefined probability distribution curve corresponds to a control for each of said organs;
step (d) involves determining, by the processor, a difference between the first probability calculated in step (c)(2) and the second probability calculated in step (c)(3) for each of said organs, and
step (e) involves determining that the difference between the first probability and the second probability calculated in step (c) is positive.

### Claim 179 (depends on 169)

The method of claim 169, wherein
i. one of at least two organs is heart and the biomarker miRNA is selected from the group consisting of miR-1, 22, 30a-3p, 30e-3p, 133a, 133b, 197, 208a, 208b, 221, 222, 302a, 302c, 367, 378, 499-5p, and 30e*; or
ii. one of at least two organs is lung and the biomarker miRNA is selected from the group consisting of miR-15b, 18b, 21, 34b, 126, 135b, 142-3p, 142-5p, 146, 146b-5p, 155, 199b-5p, 200c, 205, 211, 223, 224, 302b, 375, 449a, 449b, 450b-5p, 486, 492, 522, 566, 5′74-3p, 620, 650, 766, and 886-5p; or
iii. one of at least two organs is trachea and the biomarker miRNA is selected from the group consisting of miR-34b, 135b, 146, 146b, 147b, 155, 199b-5p, 200b, 200c, 205, 219-5p, 223, 302b, and 375; or
iv. one of at least two organs is liver and the biomarker miRNA is selected from the group consisting of miR-30e-3p, 122a, 130b, 136, 148a, 194, 376c, 455-3p, 518b, 616, 801, 885-5p, 17*, 30d*, and 194*; or
v. one of at least two organs is kidney and the biomarker miRNA is selected from the group consisting of miR-10a, 10b, 30a-3p, 30c, 107, 135a, 135b, 184, 187, 190, 194, 196b, 200a, 204, 211, 324-5p, 489, 500, 501-5p, 502-3p, 502-5p, 503, 506, 508-3p, 508-5p, 509-3p, 509-5p, 510, 532-5p, 768-3p, 886-3p, 886-5p, 891a, 10b*, 30a*, 30c-2*, 30e*, 200a*, 200b*, 424*, and 500*; or
vi. one of at least two organs is bladder and the biomarker miRNA is selected from the group consisting of miR-Let-7g, 18, 23b, 26a, 26b, 27b, 28, 106b, 143, 145, 152, 218, 221, 223, 296, 374, 422b, and 451; or
vii. one of at least two organs is breast and the biomarker miRNA is selected from the group consisting of miR-let-7a, 10b, 26a, 30a-3p, 30a-5p, 125b, 126, 145, 146, 195, 196a-2, 196b, 205, 206, 335, 339-5p, 378, 516-5p, 517c, 519c, 520g, 520h, 525, and 1246; or
viii. one of at least two organs is ovary and the biomarker miRNA is selected from the group consisting of miR-Let-7a, let-7b, let-7c, 10b, l′7-3p, 26a, 100, 125a, 125b, 127, 195, 199a-5p, 202, 214, 298, 382, 503, 672, 741, 742, 883-3p, 199a*, and 202*; or
ix. one of at least two organs is fallopian tubes and the biomarker miRNA is selected from the group consisting of miR-10a, 10b, 31, 34b, 34c, 135a, 135b, 424, and 449; or
x. one of at least two organs is uterus and the biomarker miRNA is selected from the group consisting of miR-Let-7c, 10b, 26a, 99a, 100, 125a-5p, 125b, 130a, 140, 143, 145, 195, 196b, 199b, 204, 214, 222, 939, and 199*; or
xi. one of at least two organs is cervix and the biomarker miRNA is selected from the group consisting of miR-Let-7a, let-7c, let-7 g, 10b, 100, 101, 125a-5p, 125b, 130a, 134, 140, 143, 145, 186, 195, 196b, 197, 199a, 199b, 204, 214, 218, 222, 320, 424, 497, 154*, and 199a*; or
xii. one of at least two organs is prostate and the biomarker miRNA is selected from the group consisting of miR-Let-7c, 1, 23b, 24, 27b, 28, 34a, 99a, 100, 125b, 130a, 143, 145, 147b, 187, 188-3p, 199b-5p, 205, 214, 222, 328, 373, 410, 455-5p, and 490-3p; or
xiii. one of at least two organs is testicle and the biomarker miRNA is selected from the group consisting of miR-15b, 34a, 34b, 34c, 127, 134, 135a, 135b, 187, 202, 204, 370, 372, 376a, 382, 424, 449, 465a-5p, 465b-5p, 506, 508, 509, 510, 514, 517a, 517c, 871-5p, 8′71-3p, 888, 202*, and 888*; or
xiv. one of at least two organs is spleen and the biomarker miRNA is selected from the group consisting of miR-15a, 15b, 126, 139, 142-3p, 142-5p, 146, 150, 155, 181a, 181b, 181d, 223, 302b, and 342; or
xv. one of at least two organs is thymus and the biomarker miRNA is selected from the group consisting of miR-15a, 15b, l′7-5p, 20b, 106a, 106b, 142-3p, 142-5p, 146, 149, 150, 155, 181a, 181b, 181c, 182, 183, 205, 213, and 342; or
xvi. one of at least two organs is thyroid and the biomarker miRNA is selected from the group consisting of miR-Let-7i, 1, 7, 135a, 135b, 206, and 345; or
xvii. one of at least two organs is adrenal gland and the biomarker miRNA is selected from the group consisting of miR-Let-7g, 7, 15a, 26b, 27a, 99b, 124, 127, 132, 134, 137, 139, 152, 181a, 187, 195, 192, 202, 299, 302b, 323, 324-3p, 324-5p, 328, 330-3p, 331, 335, 340, 365, 369-3p, 375, 379, 382, 409-5p, 429, 431, 432, 455-5p, 483-5p, 514, 126*, 182*, and 202*; or
xviii. one of at least two organs is pancreas and the biomarker miRNA is selected from the group consisting of miR-7, 18a, 21, 29a, 34a, 103, 12′7-3p, 129-3p, 130b, 134, 135a, 135b, 136, 141, 148a, 182, 183, 184, 192, 193a-3p, 193a-5p, 195, 199a-3p, 199a-5p, 200b, 200c, 204, 216a, 216b, 217, 224, 340, 365, 367, 374a, 374b, 375, 376a, 376c, 379, 382, 383, 429, 432, 451, 455-5p, 485-5p, 487b, 497, 539, 543, 642, 758, 939, 130b*, 136*, 183*, 200b*, and 493*; or
xix. one of at least two organs is large intestine and the biomarker miRNA is selected from the group consisting of miR-31, 141, 143, 145, 147b, 192, 194, 200a, 200b, 200bN, 200c, 200cN, 215, 219-2-3p, 321, 375, 378, 422a, 429, 450b-5p, 487a, 490-3p, 492, 504, 565, 5′74-3p, 622, 650, 801, 143*, and 200b*; or
xx. one of at least two organs is small intestine and the biomarker miRNA is selected from the group consisting of miR-31, 141, 143, 192, 194, 200a, 200b, 200bN, 200c, 200cN, 215, 321, 375, and 429; or
xxi. one of at least two organs is esophagus and the biomarker miRNA is selected from the group consisting of miR-31, 106a, 106b, 143, 145, 148a, 203, 205, 210, 211, and 221; or
xxii. one of at least two organs is stomach and the biomarker miRNA is selected from the group consisting of miR-7, 26a, 26b, 29c, 31, 106a, 106b, 124b, 130b, 141, 145, 148a, 182, 188, 192, 197, 203, 375, and 650; or
xxiii. one of at least two organs is brain and the biomarker miRNA is selected from the group consisting of miR-Let-7a, 7, 9, 96, 98, 99a, 103, 107, 124a, 125a, 125b, 127, 128a, 132, 134, 135a, 137, 138, 149, 153, 154, 181a, 181b, 181c, 182, 183, 184, 204, 211, 212, 213, 218, 219, 221, 222, 299-3p, 299-5p, 323-3p, 324-5p, 328, 329, 330, 331, 335, 337, 338, 342, 346, 369-3p, 369-5p, 370, 379, 381, 382, 383, 409-3p, 411, 425, 432, 433-5p, 485-3p, 485-5p, 487b, 488, 491-5p, 494, 495, 496, 504, 539, 541, 543, 584, 656, 668, 758, 874, 889, 935, 939, 1193, 1197, and 9*; or
xxiv. one of at least two organs is spinal cord and the biomarker miRNA is selected from the group consisting of miR-218, 219, 338, 451, and 486; or
xxv. one of at least two organs is pituitary gland and the biomarker miRNA is selected from the group consisting of miR-7, 132, 212, 213, and 328.

### Claim 180 (depends on 169)

The method of claim 169, wherein one of at least two organs is a gastrointestinal (GI) organ and the biomarker/normalizer miRNA pairs are selected from the group consisting of miR-194/miR-145, miR-194/miR148a, miR-194/miR-30e-3p, miR-215/miR-203, miR-203/miR-30e-3p, miR-203/miR148a, miR-192/miR-145, miR-192/miR148a, and miR-192/miR-30e-3p.
